<DOC>
	<DOCNO>NCT00513214</DOCNO>
	<brief_summary>The purpose study evaluate safety pharmacokinetics ( PK ) XOMA 052 subject stable Type 2 Diabetes Mellitus ( T2D ) . The study dose-escalation study design evaluate route administration ( intravenous subcutaneous ) , dose , dose regimen future study .</brief_summary>
	<brief_title>Safety Pharmacokinetics Study XOMA 052 Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>American Diabetes Association ( ADA ) diagnostic criterion T2D Fasting blood glucose concentration ≥ 126 mg/dL ( ≥ 7.0 mmol/L ) ( must measure within 35 day prior Day 0 ) OR Symptoms hyperglycemia ( e.g. , thirst , polyuria , weight loss , visual blurring ) AND casual/random plasma glucose value ≥ 200 mg/dL ( ≥ 11.1 mmol/L ) ( must measure within 35 day prior Day 0 ) HbA1c ≥ 7.5 % ≤ 12 % ( DCCT standard ) Current T2D duration &gt; 6 month Screening T2D disease must stable . Stable disease define disease judge stable investigator require change medication dose level 4 consecutive day 7 day total within 35 day prior Day 0 . Age ≥ 18 ≤ 70 Screening Weight ≥ 80 lb ( 36.3 kg ) ≤ 325 lb ( 147.4 kg ) BMI ≥ 23 ≤ 40 kg/m2 For female subject childbearing age , negative serum pregnancy test . For subject reproductive potential , willingness use contraceptive measure adequate prevent subject subject 's partner become pregnant study . Agree change diet exercise regimen trial Use follow medication Antiinflammatory therapy aspirin ≤ 100 mg/day ; Immunosuppressive treatment ; Beta 2 nonselective adrenergic blocker ( Note : selective beta 1 blocker permit ) ; Thiazolidinediones ; Glucagonlike peptide ( GLP ) agonists include DPP4 inhibitor Change medication diabetes within 35 day prior Day 0 , define change dose level 4 consecutive day 7 day total Fasting Cpeptide &lt; 400 pM ( &lt; 1.20 μg/L ) Hemoglobin &lt; 8.0 g/dL , WBC &lt; 3.0 X 103/mm3 , platelet count &lt; 125 X 103/mm3 , creatinine &gt; 1.5 mg/dL , AST/ALT &gt; 2 X ULN , alkaline phosphatase &gt; 2 X ULN Positive GAD65 IA2 autoantibody Known HIV antibody , hepatitis B surface antigen , and/or hepatitis C antibody History malignancy within 5 year prior study entry carcinoma situ cervix , adequately treat , nonmetastatic squamous basal cell carcinoma skin History severe allergic anaphylactic reaction humanize murine monoclonal antibody History tuberculosis , positive PPD test , active atopic disease require medication , asthma Infectious disease CRP &gt; 30 mg/L , fever , infection require treatment antibiotic within 3 week prior Screening ; History recurrent infection predisposition infection ; Active leg foot ulcer Immunodeficiency Female subject pregnant , plan become pregnant course study , breastfeed History symptom demyelinate disease Clinically significant diabetic macular edema and/or proliferative diabetic retinopathy history fundoscopy Receipt live ( attenuate ) vaccine within 3 month prior Screening Major surgery within 35 day prior Day 0 Participation investigational drug device trial within 30 day prior Screening Use therapeutic monoclonal antibody within 90 day prior Screening Any condition , opinion investigator , would jeopardize subject 's safety follow exposure study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 2</keyword>
	<keyword>Mellitus</keyword>
</DOC>